Patented Formulations Designed for Eye Health
MaculaPM®
Support Macula & Retina Health
MaculaPM® is a science-driven, doctor-derived, supplement formulated to support macular and retinal health while you rest and recharge at night.
Featuring L-DOPA, Melatonin, and other clinically studied nutrients, MaculaPM® is designed to help protect the macula and support long-term retinal function.
With Free Shipping ● Less than $1 per day!
Plus Shipping Costs
MaculaPM® Ingredients
Proactive Eye Health for Your Macula & Retina
L-DOPA
L-DOPA is the key ingredient that makes MaculaPM® different from standard eye health supplements. We included it based on scientific research supporting its role in healthy retinal function and visual signaling.
Vitamin C
Vitamin C helps support the eye’s natural antioxidant defenses. We included it to help protect cells from oxidative stress and support overall eye wellness.
Vitamin E
Vitamin E is a key antioxidant that helps support cell health by protecting against free radical damage. We included it as part of a comprehensive nutritional approach to long-term eye health.
Melatonin
Melatonin was included because it is a natural nighttime compound that supports the body’s normal overnight restorative processes. It also provides antioxidant support, making it a strong fit for MaculaPM®’s nighttime formula.
Lutein
Lutein is one of the best-known nutrients for macular health. We included it to support macular pigment, visual performance, and the eye’s natural ability to filter blue light.
Zeaxanthin
Zeaxanthin works together with lutein and is also concentrated in the macula. We included it to support central visual function, macular health, and antioxidant protection.
Learn More About How the MaculaPM® Formulation Acts to Protect the Macula from AMD
Patient Testimonial
This patient has been taking L-DOPA and Melatonin supplements (the key ingredients in the MaculaPM® formulation) for over 10 years.
L-DOPA & Melatonin Research
Dr. Snyder discusses the clinical research related to the use of Melatonin and L-Dopa for patients concerned about AMD (age-related macular degeneration.)
The Origin of MaculaPM
John Martens shares the origin story for MaculaPM®, recalling how genetic research into causes and prevention of blindness led to the creation of MaculaPM®.
About Tech Launch Arizona
The University of Arizona is a place of learning, invention and discovery. Tech Launch Arizona collaborates with creators and the local community to help bring those discoveries to the world through commercial pathways. MaculaPM® benefited from research conducted at the University of Arizona and licensed the formulation from Tech Launch Arizona.
Meet the Medical Team Behind MaculaPM®
Robert W. Snyder, MD, PhD, PC
Dr. Snyder has extensive clinical ophthalmologic experience as well as a PhD in microbiology/cell biology. He has received peer reviewed funding for both clinical research and trials, as well as basic research. He served as the Chairman of Ophthalmology at The University of Arizona where he received numerous grants, conducted clinical trials, and secured NIH funding for eye research.
Dr. Brian McKay
Dr. McKay is a leading researcher with extensive experience in ophthalmology, macular degeneration and other vision-related research. Dr. McKay earned his Ph.D. at the Medical College of Wisconsin. He also received postdoctoral training at The Scripps Institute, and he currently serves as a course director in the vision science colloquium at the University of Arizona.
John A. Martens
With degrees in Chemical Engineering and Chemistry, John Martens has decades of experience as a scientist, engineer and product innovator. He served as a corporate scientist for 35 years at 3M Corporation, and he has been involved in the development of products and technologies for numerous nutraceutical, pharmaceutical and biomedical products related to the treatment of eye diseases.
Dr. Murray H. Brilliant
Dr. Brilliant has a degree in Biology and received his doctorate in Molecular Cell & Developmental Biology. He is currently a professor of Ophthalmology at the University of Arizona where he has a research focus in areas related to macular degeneration. Dr. Brilliant headed the research project that identified the profound protective benefits of L-DOPA on age-related macular degeneration.
